protein phosphatase, Mg2+/Mn2+ dependent 1MGenealiases: PP2C-eta · PP2CE · PP2Ceta
Q-omics provides the consensus-scored PPM1M profile across patient tissues and cancer cell-line models. PPM1M expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PPM1M is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PPM1M RNA expression shows 20,306 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where PPM1M shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1M — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1M survival associations across molecular data types. PPM1M RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1M RNA expression–survival associations across cancer types. High PPM1M expression shows unfavorable associations in KIRC, LGG and ACC, but favorable associations in HNSC, LUAD and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PPM1M RNA expression.
This table summarizes PPM1M tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PPM1M. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1M shows lower tumor expression in BLCA, LUSC, LUAD and KICH and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher PPM1M RNA expression in normal versus tumor tissue (log2 FC = −1.450, t-test p < 0.001).
This table shows molecular features associated with PPM1M in patient tissues and cancer cell lines. In patient samples, PPM1M shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPM1M RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
